⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL702714 | 0.79 | — | — | |
| SCHEMBL127281 | 0.75 | — | — | |
| SCHEMBL158133 | 0.75 | — | — | |
| SCHEMBL62327 | 0.70 | — | — | |
| SCHEMBL17894914 | 0.69 | — | — | |
| SCHEMBL232474 | 0.68 | — | — | |
| SCHEMBL1031265 | 0.68 | — | — | |
| SCHEMBL102447 | 0.68 | — | — | |
| SCHEMBL717094 | 0.68 | — | — | |
| SCHEMBL5095094 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109937238-A | Cell-penetrating fluorescent dyes with secondary alcohol functional groups | 马克斯-普朗克科学促进学会 | 2019-06-25 | — | — | CN | claimed |
| CN-105837411-B | The composition and method inhibited for glucose transport | 俄亥俄州立大学 | 2019-06-18 | — | — | CN | claimed |
| CN-102917590-B | Tricyclic compound and the PBK inhibitor containing described compound | ONCOTHERAPY SCIENCE, INC. (JP) | 2016-02-17 | — | — | CN | claimed |
| CN-103037690-A | Compositions and methods for glucose transport inhibition | UNIV OHIO | 2013-04-10 | — | — | CN | claimed |
| JP-4726235-B2 | — | — | 2011-07-20 | — | — | JP | claimed |
| US-7687639-B2 | Substituted benzimidazoles and imidazo-[4,5]-pyridines | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-03-30 | — | — | US | claimed |
| EP-1773860-A4 | METHODS FOR IDENTIFYING RISK OF TYPE II DIABETES AND TREATMENTS THEREOF | SEQUENOM INC (US) | 2009-05-06 | — | — | EP | claimed |
| US-7504414-B2 | Substituted benzimidazoles and imidazo-[4,5]-pyridines | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2009-03-17 | — | — | US | claimed |
| US-20080009493-A1 | Substituted Benzimidazoles and Imidazo-[4,5]-Pyridines | ARIENTI KRISTEN L | 2008-01-10 | — | — | US | claimed |
| US-7271261-B2 | Substituted benzimidazoles and imidazo-[4,5]-pyridines | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2007-09-18 | — | — | US | claimed |
| US-20030176438-A1 | Substituted benzimidazoles and imidazo-[4,5]-pyridines | ORTHOMCNEIL PHARMACEUTICAL, INC. | 2003-09-18 | — | — | US | claimed |
| CN-1116286-C | 4-anilinoquinazoline derivatives | ZENECA LTD (GB) | 2003-07-30 | — | — | CN | claimed |
| WO-2003032984-A1 | 2-PHENYL BENZIMIDAZOLES AND IMIDAZO-[4,5]-PYRIDINES AS CDSI/CHK2-INHIBITORS AND ADJUVANTS TO CHEMOTHERAPY OR RADIATION THERAPY IN THE TREATMENT OF CANCER | ORTHO-MCNEIL PHARMACEUTICAL,INC. (US) | 2003-04-24 | — | — | WO | claimed |
| US-6514971-B1 | For use in the production of antiangiogenic and/or vascular permeability reducing effects in warm-blooded animals such as humans | ZENECA LIMITED (GB) | 2003-02-04 | — | — | US | claimed |
| EP-0885198-B1 | 4-ANILINOQUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-12-19 | — | — | EP | claimed |
| CN-1212684-A | 4-anilinoquinazoline derivatives | ZENECA LTD (GB) | 1999-03-31 | — | — | CN | claimed |
| EP-0888310-A1 | CINNOLINE DERIVATIVES AND USE AS MEDICINE | ZENECA LIMITED (GB) | 1999-01-07 | — | — | EP | claimed |
| EP-0885198-A1 | 4-ANILINOQUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1998-12-23 | — | — | EP | claimed |
| WO-1997034876-A1 | CINNOLINE DERIVATIVES AND USE AS MEDICINE | ZENECA LIMITED (GB) | 1997-09-25 | — | — | WO | claimed |
| WO-1997032856-A1 | 4-ANILINOQUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1997-09-12 | — | — | WO | claimed |